Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. announced its unaudited financial results for the third quarter of 2025, revealing a slight decline in revenue and net profit compared to the previous year. The company reported a 1.89% decrease in quarterly revenue and a 9.58% drop in net profit attributable to shareholders. Despite these declines, the company’s total assets increased by 6.31% from the end of last year, indicating a potential strengthening of its financial position. However, the net cash flow from operating activities showed a significant negative change, highlighting challenges in operational cash management.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. It is engaged in the distribution and retail of pharmaceutical and healthcare products, with a market focus on both A shares and B shares listed on the Shenzhen Stock Exchange.
Average Trading Volume: 5,393,276
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$60.31B
See more insights into 1099 stock on TipRanks’ Stock Analysis page.